The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hormonal contraceptive market is expected to grow at a CAGR of around 4% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hormonal contraceptives are formulations of progestin or a combination of estrogen and progesterone hormones. They act on the endocrine system to prevent ovulation and fertilization. As a result, they are used for preventing unwanted pregnancies and are also known to relieve period pain and often result in lighter periods. Hormonal contraceptives are considered one of the most effective methods, which can be taken before and after vaginal intercourse. They include birth control pills, vaginal rings, contraceptive skin patches, and hormone-releasing contraceptive coils. Hormonal contraceptives also affect the womb lining, making it hard for the fertilized eggs to be implanted.
The global hormonal contraceptive market is primarily driven by the increasing awareness among the masses regarding family planning. This has facilitated the need to prevent unintended pregnancies, especially among young couples. Furthermore, a significant rise in health issues associated with teenage pregnancies is promoting the use of contraceptives as they are easily accessible. Governments of different countries are also adopting various initiatives to support and improve access to these products by promoting affordable and high-quality healthcare services. Besides this, the advancements in the healthcare industry have resulted in the production of innovative products such as hormonal patches, implants, intrauterine devices, and drug-device combination products. These devices have fewer side effects and enhanced levels of efficiency in preventing pregnancy, which is favorably influencing the growth of the market
IMARC Group provides an analysis of the key trends in each sub-segment of the global hormonal contraceptive market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, hormone, age group and end user.
Breakup by Product:
Breakup by Hormone:
Breakup by Age Group:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Afaxys Inc., Agile Therapeutics Inc., Allergan Inc. (AbbVie Inc.), Bayer AG, Cipla Limited, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Piramal Group and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Hormone, Age Group, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Afaxys Inc., Agile Therapeutics Inc., Allergan Inc. (AbbVie Inc.), Bayer AG, Cipla Limited, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Piramal Group and Teva Pharmaceutical Industries Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at